These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17431776)

  • 21. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    J Interferon Cytokine Res; 2008 Oct; 28(10):623-9. PubMed ID: 18778199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
    Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G;
    J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marked reduction of the alpha-fetoprotein levels among individuals with chronic hepatitis C, following PEG-interferon and ribavirin treatment.
    Aladag M; Camci C; Huang Y; Wright H; Rizvi S; Gurakar A; Stokes K; Sebastian A
    J Clin Gastroenterol; 2005; 39(10):923-4. PubMed ID: 16208125
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation.
    Knapstein J; Galle PR; Zimmermann T
    Dig Liver Dis; 2014 Jan; 46(1):88-9. PubMed ID: 24054768
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
    Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin.
    Trebst C; Wedemeyer H; Manns MP; Tillmann H; Windhagen A
    Eur J Gastroenterol Hepatol; 2007 Jan; 19(1):91-2. PubMed ID: 17206084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
    Ohara T; Oteki T; Suzuki T; Suzuki M; Matsuzaki Y
    Hepatogastroenterology; 2011; 58(105):133-6. PubMed ID: 21510300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes.
    Berenguer M; Ortíz-Cantó C; Abellán JJ; Aguilera V; Rubín A; Prieto M; López-Labrador FX
    J Clin Virol; 2012 Mar; 53(3):231-8. PubMed ID: 22222052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remission of HCV-associated glomerulonephritis with pegylated ifn and ribavirin therapy after liver transplantation: case report and literature review.
    Donato MF; Fabrizi F; Fogazzi GB; Cresseri D; Passerini P; Martin P; Messa P
    Int J Artif Organs; 2013 Jan; 36(1):63-8. PubMed ID: 23280083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy.
    Aghemo A; Rumi MG; De Nicola S; Colombo M
    Hepatology; 2010 Sep; 52(3):1170-1. PubMed ID: 20812363
    [No Abstract]   [Full Text] [Related]  

  • 32. Response-guided therapy: optimizing treatment now and in the future.
    Marcellin P; Rizzetto M
    Antivir Ther; 2008; 13 Suppl 1():1-2. PubMed ID: 18432156
    [No Abstract]   [Full Text] [Related]  

  • 33. Response of Black African patients with hepatitis C virus genotype 4 to treatment with peg-interferon and ribavirin.
    Nkuize M; Mulkay JP; Adler M; Lasser L; Michielsen P; de Galocsy C; Assene C; Delwaide J
    Acta Gastroenterol Belg; 2013 Sep; 76(3):291-9. PubMed ID: 24261022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.
    Zeuzem S
    J Hepatol; 2008 Aug; 49(2):157-9. PubMed ID: 18554745
    [No Abstract]   [Full Text] [Related]  

  • 35. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.
    Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
    Hepatology; 2009 Jun; 49(6):2125; author reply 2125-6. PubMed ID: 19479790
    [No Abstract]   [Full Text] [Related]  

  • 36. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy.
    Liu CH; Liang CC; Liu CJ; Tsai HB; Hung PH; Hsu SJ; Chen SI; Lin JW; Lai MY; Chen JH; Chen PJ; Chen DS; Kao JH
    Gut; 2009 Feb; 58(2):314-6. PubMed ID: 19136527
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of re-treatment by peginterferon alpha-2a and ribavirin in a child with hepatitis C.
    Nishimata S; Tsutsumi N; Suzuki S; Nagao R; Kashiwagi Y; Kawashima H
    J Infect Chemother; 2014 Jul; 20(7):443-5. PubMed ID: 24793175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.
    Ferenci P; Scherzer TM; Kerschner H; Rutter K; Beinhardt S; Hofer H; Schöniger-Hekele M; Holzmann H; Steindl-Munda P
    Gastroenterology; 2008 Nov; 135(5):1561-7. PubMed ID: 18771667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case report: Cure of chronic infection with hepatitis C virus after 6 weeks of peg-interferon and ribavirin in a patient co-infected with HIV.
    Rachline A; Palmer P; Simon F; Molina JM
    J Med Virol; 2010 Jul; 82(7):1150-1. PubMed ID: 20513077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.